Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

NCT00035022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic
Lymphoma

Interventions

DRUG: BCX-1777

Sponsor

BioCryst Pharmaceuticals